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Abstract The plant toxin ricin has proven valuable as a
membrane marker in studies of endocytosis as well as studies
of different intracellular transport steps. The toxin, which
consists of two polypeptide chains, binds by one chain (the B-
chain) to both glycolipids and glycoproteins with terminal
galactose at the cell surface. The other chain (the A-chain)
enters the cytosol and inhibits protein synthesis enzymatically.
After binding the toxin is endocytosed by different mechanisms,
and it is transported via endosomes to the Golgi apparatus and
the endoplasmic reticulum before translocation of the A-chain to
the cytosol. The different transport steps have been analyzed by
studying trafficking of ricin as well as modified ricin molecules.
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1. Introduction
Ricin belongs to a group of plant and bacterial protein
toxins that bind to cells and inhibit protein synthesis enzy-
matically after entry of part of the toxin into the cytosol [1].
This group of toxins includes diphtheria toxin, Shiga toxin,
Pseudomonas exotoxin A, abrin and modeccin. The enzymati-
cally active moiety of ricin is able to inactivate about 2000
ribosomes per minute, and the entry of a few molecules into
the cytosol will therefore have a dramatic e¡ect on the cell [2].
Thus, toxicity serves as a very sensitive test system to monitor
entry of toxin into the cytosol. The extreme toxicity of mol-
ecules such as ricin is also the basis for their use in construc-
tion of target-speci¢c toxins. In these molecules either the
enzymatically active subunit or a larger part of the toxin mol-
ecule is coupled to an antibody directed against certain cell
types or to another cell surface binding molecule such as
transferrin. Clinical studies of such hybrid toxins now show
promising results [3,4].
Ricin has proven useful to study di¡erent endocytic proc-
esses [1,5,6]. Since it binds to both glycoproteins and glyco-
lipids with terminal galactose, it labels the cell surface and will
be endocytosed by any structure that pinches o¡ (Fig. 1). In
the case of endocytosis studies, 125I-labeled ricin as well as
horseradish peroxidase (HRP)-labeled ricin are useful
markers. Moreover, by using these modi¢ed ricin molecules
and cell fractionation as well as electron microscopy, we have
also studied the transport of ricin from endosomes to the
Golgi apparatus in non-polarized as well as in polarized cells.
Recently, ricin molecules containing a sulfation site that can
be modi¢ed in the trans-Golgi network (TGN) have proven
valuable to quantify entry into the Golgi apparatus [5,7]. Fur-
thermore, ricin molecules with both a sulfation site and gly-
cosylation sites can be used to monitor retrograde transport
through the Golgi apparatus and to the endoplasmic reticu-
lum (ER), and ricin can therefore be used not only to study
endocytosis but also to investigate transport between di¡erent
organelles of the cell [5,7]. As discussed below, studies of toxin
transport are not only useful to characterize already known
transport routes in a cell, but they can also reveal new path-
ways.
2. Endocytic uptake of ricin
Early studies with ricin revealed that although the well-
characterized clathrin-dependent endocytosis clearly is in-
volved in uptake of ricin into endosomes, ricin can also be
internalized by clathrin-independent mechanisms (for review,
see [1]). Thus, acidi¢cation of the cytosol which inhibits for-
mation of clathrin-coated vesicles from clathrin-coated pits in
all cell types tested so far [8], as well as potassium depletion
which removes clathrin-coated pits from the membrane in
some cell types [9,10], blocked uptake of transferrin, whereas
ricin endocytosis continued. More recent evidence for clath-
rin-independent endocytosis comes from studies where cells
with inducible expression of mutant dynamin, which inhibits
clathrin-dependent endocytosis, were used. In these cells both
£uid and ricin were endocytosed upon expression of mutant
dynamin [5,11]. Also, studies of cells expressing a dominant-
negative fragment of clathrin heavy chain [12], thereby inter-
fering with clathrin-dependent uptake, revealed the presence
of clathrin-independent endocytosis.
Clathrin-independent endocytosis can clearly be di¡erent
from uptake which might occur from caveolae, the small chol-
esterol-rich invaginations reported to pinch o¡ and form
vesicles in endothelial cells and some other cell types [13^17]
(Fig. 1). Thus, there is clathrin-independent endocytosis in
lymphocytes [18] which do not have caveolae [19], and there
is a highly regulated form of clathrin-independent endocytosis
on the apical side of polarized MDCK cells [20^22], in which
all of the caveolae are found at the basolateral side [23]. The
role of this interesting polarizaton of caveolae is not known. It
should be noted that mutant dynamin has been reported to
inhibit formation of vesicles also from caveolar structures
[14,15], and the clathrin-independent endocytosis of ricin oc-
curring in HeLa cells expressing mutant dynamin is therefore
clearly independent of these structures. Also, the HeLa cells
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with inducible synthesis of mutant dynamin have few or no
caveolae that could have contributed to the uptake of ricin.
Caveolae are covered by caveolin on the cytosolic side of
the membrane, and there is evidence that the two isoforms
caveolin-1 and caveolin-2 are required for their formation
[24]. It is an old observation that caveolar structure and func-
tion are dependent on membrane cholesterol [25]. Upon addi-
tion of ¢lipin or other drugs that form complexes with chol-
esterol there are no invaginated caveolar structures at the cell
membrane [26], and also, when cholesterol is removed by
addition of cyclodextrin [27], caveolae are removed [6,28].
Remarkably, it turns out that the invagination of clathrin-
coated pits is also dependent on cholesterol [6]. When HEp-
2 cells, MDCK cells, A431 cells or NIH3T3 cells are treated
with methyl-L-cyclodextrin to selectively remove cholesterol
from the membrane, not only are caveolae a¡ected, but also
transferrin endocytosis is strongly inhibited. Detailed morpho-
logical studies of the HEp-2 cells revealed that after cyclo-
dextrin treatment few invaginated clathrin-coated pits could
be seen, suggesting that there is an inhibition of invagination
of this structure. The concentration of the transferrin receptor
in the clathrin-coated areas of the membrane was the same in
control cells and in cyclodextrin-treated cells. Interestingly,
the £attened coated pits in cholesterol-depleted cells were
not distributed at random but appeared in microdomains of
two to four, suggesting that preexisting clathrin assemblies on
the membrane act as nucleation sites for the binding of clath-
rin and formation of new coated pits (Fig. 2). It is, however,
not clear whether cholesterol is required in the clathrin-coated
invaginated structure or whether it is required for signaling
involved in inducing formation of this structure. Importantly,
endocytosis of ricin continues in cells where the function of
clathrin-coated pits and caveolae has been perturbed by ex-
traction of cholesterol with cyclodextrin, providing yet anoth-
er demonstration of endocytosis which is independent of both
clathrin and caveolae, and which functions with a lower con-
centration of cholesterol in the membrane than the two other
pathways.
What sort of mechanisms are involved in clathrin- and cav-
eolae-independent endocytosis? The data so far suggest that
there is more than one mechanism involved. In addition to
macropinocytosis (formation of relatively large vesicular
structures where the vesicle formation is dependent on PI-3
kinase [29]) which we will not go further into in this short
review, we have already discussed that there is clathrin-inde-
pendent endocytosis of ricin which is independent of dynamin.
It has, however, been reported that the clathrin-independent
endocytosis occurring after induced exocytosis in some cell
types is dependent on dynamin [30]. Clathrin-independent en-
docytosis can be di¡erentially regulated at the apical and the
basolateral side of polarized cells [20^22]. However, the phys-
iological role of such a regulation is not known. In polarized
MDCK cells apical clathrin-independent endocytosis can be
upregulated both by activation of protein kinase A and C, by
heterotrimeric G proteins and by calmodulin antagonists
without any concomitant e¡ect on the basolateral endocytosis.
Remarkably, recent results demonstrate that the apical clath-
rin-independent endocytosis, in contrast to other endocytic
processes described so far, functions in the presence of
GTPQS, and that it is regulated by Rho proteins (Ò. Garred,
K. Rodal, B. van Deurs and K. Sandvig, submitted). Whether
there is a similar regulation at the basolateral side is not yet
known. Also in other cells a regulation of the clathrin-inde-
pendent uptake has been shown. In HeLa cells expressing
mutant dynamin there seems to be an upregulation of the
clathrin-independent endocytosis [31,32]. Impressively, the to-
tal £uid and ricin uptake in these cells seems to end up at the
original level after this upregulation. It is unknown how the
cells are able to control the level of membrane taken in under
Fig. 1. Surface structures proposed to be involved in endocytosis.
Fig. 2. E¡ect of methyl-L-cyclodextrin on clathrin-coated pits. Ar-
rows in A and B show a deeply invaginated clathrin-coated pit and
a coated vesicular pro¢le as seen in control cells. C shows a £at
(non-invaginated) region of the plasma membrane with clathrin as-
sembly (between small arrows) following cholesterol extraction with
methyl-L-cyclodextrin. D shows a £attened area of the plasma mem-
brane associated with clathrin (between small arrows) from another
cyclodextrin experiment where the cells were labeled with immuno-
gold [6] to demonstrate that transferrin receptors (arrowheads) are
still present in the £attened clathrin-coated pits found in cells after
cholesterol extraction. Bar, 100 nm.
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the di¡erent conditions. It is therefore di⁄cult to estimate the
quantitative role of the di¡erent endocytic mechanisms. Con-
ditions that interfere with one process, such as the ability of
cytosolic acidi¢cation to inhibit uptake from clathrin-coated
pits [8], might on the one hand also have some inhibitory
e¡ect on other endocytic processes, on the other hand one
cannot exclude that the inhibition of one process upregulates
the other. Anyway, cytosol acidi¢cation reduces ricin endocy-
tosis to about 50% in a number of di¡erent cell types.
A large number of physiologically important molecules are
known to enter by clathrin-dependent endocytosis (for review,
see [33]), but there are also physiologically important mole-
cules entering by clathrin- and caveolae-independent endocy-
tosis. The ¢rst example published was the uptake of interleu-
kin-2 in lymphocytes [18]. Now there are other examples as
well : angiotensin [34], M2 muscarinic receptors [35] as well as
D2 dopamine receptors (in contrast to D1 dopamine recep-
tors) [36] are reported to be internalized by a dynamin-inde-
pendent endocytic process. The appearance of physiologically
important molecules entering by this mechanism (or these
mechanisms) might facilitate the investigation of the process
as such. We would like to stress that also the clathrin-depend-
ent endocytosis might turn out to consist of more than one
mechanism [37] and be di¡erentially regulated [38]. Also with
respect to the regulation of clathrin-dependent endocytosis
there seem to be di¡erences in its regulation at the apical
and basolateral side in a polarized cell [38].
3. Transport of ricin from endosomes to the TGN
After endocytosis ricin is transported through the endoso-
mal system to lysosomes, and the toxin can also be found in
the Golgi apparatus [1]. As mentioned in Section 1, ricin
transport to this organelle can be monitored by cell fractio-
nation after incubation with 125I-labeled ricin, by electron
microscopy of cells labeled with HRP-ricin, or by sulfation
of ricin modi¢ed to contain a sulfation site. Such studies have
revealed that mutant dynamin inhibits ricin transport from
endosomes to the Golgi apparatus suggesting that dynamin-
2 or a dynamin-like molecule is involved in this transport step
[5]. The studies also show that ricin transport to the Golgi
apparatus occurs independently of low endosomal pH [1].
Thus there is no requirement for a low pH-dependent forma-
tion of any carrier vesicle which has been reported to be in-
volved in transport from early to late endosomes in some cell
types [39]. It should, however, be noted that transport from
early to late endosomes may occur by maturation [40]. In for
instance HEp-2 cells [41], internalized ligands can be trans-
ported to late endosomes in the presence of ba¢lomycin which
will inhibit the endosomal proton pump and increase the pH
in these compartments [41]. Not only is ricin transport to the
Golgi apparatus occurring in the absence of low endosomal
pH, ricin transport to the Golgi apparatus can actually be
enhanced by addition of monensin which will abolish the
low endosomal pH [1]. Furthermore, ricin transport to the
Golgi apparatus can be regulated by cAMP [42] and by cal-
modulin inhibitors [22]. It should be noted that the amount of
ricin entering the Golgi apparatus of polarized MDCK cells is
di¡erentially regulated depending on whether ricin is endocy-
tosed from the apical or the basolateral pole of the cells
[1,22,42]. These ¢ndings are in agreement with the idea that
ricin might enter the Golgi apparatus by another route than
the only route from endosomes to the Golgi apparatus that
has been characterized so far, the Rab9-dependent transport
from late endosomes [43]. It has recently been suggested that
Shiga toxin [44] and TGN38 [45] move directly from the peri-
nuclear recycling compartment to the TGN, without involve-
ment of late endosomes. This conclusion was partially based
on the ¢nding that none of the molecules could be visualized
in late endosomes (Fig. 3). However, this does not mean that
they are not transported through this organelle at a concen-
tration which is too low to be seen by microscopy. For in-
stance, ricin has never been observed by microscopy in the
ER, but by using the modi¢ed ricin that contains a glycosyl-
ation site, ricin localization in the ER can nevertheless be
demonstrated by measuring glycosylation of ricin entering
this compartment [5,7]. One way to study whether ricin is
routed to the Golgi apparatus via the Rab9-dependent path-
way from late endosomes is to express mutant Rab9 in an
inducible manner to block the Rab9-dependent transport
[43]. Results from such experiments support the idea that ricin
actually enters the Golgi apparatus independently of Rab9,
but at present one cannot say whether the Rab9-independent
transport occurs from late endosomes or from an earlier com-
partment (T.-G. Iversen, A. Llorente, P. Nicoziani, B. van
Deurs and K. Sandvig, submitted).
4. Retrograde transport of ricin to the ER and translocation to
the cytosol
The ¢rst toxin found to be transported all the way from the
cell surface, through endosomes and the Golgi apparatus and
to the ER was the glycolipid binding bacterial toxin Shiga
toxin [46,47]. Later on a similar retrograde transport was
shown for cholera toxin [48] and ricin [7]. In the case of ricin
it was demonstrated that toxin molecules with glycosylation
sites that were modi¢ed in the ER were actually transported
to the cytosol. Remarkably, in contrast to cholera toxin [49],
neither ricin [50] nor Shiga toxin [51^53] has a KDEL se-
quence that might facilitate the retrograde transport to the
ER. It is not known, and clearly a goal for future studies to
investigate, whether the retrograde transport of these mole-
cules occurs in the same way as those with a KDEL sequence.
When ¢nally arriving in the ER it is still unknown how the
toxin molecules enter the cytosol. However, the recent studies
of transport from the ER to the cytosol by the sec61 complex
[54] make it tempting to suggest that toxins might exploit this
mechanism to gain access to the cytosol. Once in the cytosol
they can then exert their ¢nal action: both Shiga toxin and
Fig. 3. Transport routes between endosomes and the Golgi appara-
tus. EE, early endosomes; LE, late endosomes; LY, lysosomes.
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ricin inactivate the 60S subunit of the ribosomes [2] and there-
by they kill the cells.
5. Conclusions
Studies of uptake and intracellular transport of ricin are
useful to elucidate the various endocytic mechanisms. Clearly
we need to learn more about the clathrin-independent mech-
anisms. Why do the cells have these mechanisms and why and
how are they regulated? Studies of ricin transport in the ret-
rograde directions to the Golgi and the ER can furthermore
provide us with information about these transport steps, and
might even reveal new pathways not easily discovered by stud-
ies of endogenous molecules. Investigations of protein toxins
as such might also facilitate construction of molecules that
could be bene¢cial in treatment of disease.
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